$EXEL
EXELIXIS, INC. Stock $exel

$exel Overview Financials Valuation SEC Filings Company Website

2016 Q1 Form 10-Q Financial Statement

#000093976716000188 Filed on May 04, 2016

Income Statement

Concept	2016 Q1	2015 Q4	2015 Q1
Revenue	$15.43M	$9.938M	$9.388M
YoY Change	64.33%	35.16%	91.4%
Cost Of Revenue	$685.0K	$1.000M	$766.0K
YoY Change	-10.57%	42.86%	147.9%
Gross Profit	$8.414M	$8.915M	$8.622M
YoY Change	-2.41%	33.68%	87.6%
Gross Profit Margin	54.54%	89.71%	91.84%
Selling, General & Admin	$34.86M	$17.10M	$9.531M
YoY Change	265.72%	74.49%	-35.12%
% of Gross Profit	414.27%	191.81%	110.54%
Research & Development	$28.93M	$23.50M	$22.28M
YoY Change	29.82%	-40.81%	-59.37%
% of Gross Profit	343.78%	263.6%	258.43%
Depreciation & Amortization	$229.0K	$300.0K	$297.0K
YoY Change	-22.9%	-150.0%	-40.36%
% of Gross Profit	2.72%	3.37%	3.44%
Operating Expenses	$64.56M	$40.60M	$32.15M
YoY Change	100.83%	-17.81%	-54.0%
Operating Profit	-$49.14M	-$31.60M	-$22.76M
YoY Change	115.88%	-31.61%	-64.98%
Interest Expense	$10.29M	-$9.900M	$12.40M
YoY Change	-17.04%	-16.81%	5.45%
% of Operating Profit
Other Income/Expense, Net	-$10.09M		-$12.41M
YoY Change	-18.71%		28.85%
Pretax Income	-$59.22M	-$41.50M	-$35.20M
YoY Change	68.25%	-28.57%	-52.82%
Income Tax	$0.00	$100.0K
% Of Pretax Income
Net Earnings	-$59.22M	-$41.57M	-$33.25M
YoY Change	78.14%	-28.27%	-55.45%
Net Earnings / Revenue	-383.89%	-418.27%	-354.12%
Basic Earnings Per Share	-$0.26
Diluted Earnings Per Share	-$0.26	-$182.9K	-$179.7K
COMMON SHARES
Basic Shares Outstanding	228.3M shares	227.2M shares	195.9M shares
Diluted Shares Outstanding	228.3M shares

Balance Sheet

Concept	2016 Q1	2015 Q4	2015 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$322.1M	$167.1M	$107.2M
YoY Change	200.47%	15.8%	-60.82%
Cash & Equivalents	$141.6M	$141.6M	$80.40M
Short-Term Investments	$45.20M	$25.40M	$22.30M
Other Short-Term Assets	$4.800M	$3.800M	$11.30M
YoY Change	-57.52%	-75.8%	-35.8%
Inventory	$2.472M	$2.616M	$2.593M
Prepaid Expenses
Receivables	$10.10M	$5.200M	$3.900M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$339.5M	$178.7M	$125.0M
YoY Change	171.49%	6.83%	-58.08%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.813M	$1.434M	$2.158M
YoY Change	-15.99%	-41.04%	-53.94%
Goodwill	$63.68M	$63.68M	$63.68M
YoY Change	0.0%	0.0%	0.0%
Intangibles
YoY Change
Long-Term Investments	$82.90M	$83.60M	$81.60M
YoY Change	1.59%	2.45%	-26.62%
Other Assets	$2.068M	$2.309M	$7.771M
YoY Change	-73.39%	-36.72%	-12.86%
Total Long-Term Assets	$153.1M	$153.7M	$157.9M
YoY Change	-3.06%	-1.51%	-20.76%
TOTAL ASSETS
Total Short-Term Assets	$339.5M	$178.7M	$125.0M
Total Long-Term Assets	$153.1M	$153.7M	$157.9M
Total Assets	$492.5M	$332.3M	$282.9M
YoY Change	74.08%	2.81%	-43.14%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$5.657M	$6.401M	$1.303M
YoY Change	334.15%	-0.19%	-73.64%
Accrued Expenses	$16.14M	$18.07M	$30.98M
YoY Change	-47.91%	-56.5%	-20.81%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$27.50M	$0.00	$4.075M
YoY Change	574.85%	-100.0%	192.74%
Total Short-Term Liabilities	$101.1M	$52.25M	$58.68M
YoY Change	72.23%	-69.34%	-17.42%
LONG-TERM LIABILITIES
Long-Term Debt	$361.2M	$417.9M	$364.4M
YoY Change	-0.88%	61.28%	6.65%
Other Long-Term Liabilities	$1.317M	$2.960M	$2.961M
YoY Change	-55.52%	-29.0%	-45.84%
Total Long-Term Liabilities	$362.5M	$420.9M	$367.3M
YoY Change	-1.32%	59.85%	5.83%
TOTAL LIABILITIES
Total Short-Term Liabilities	$101.1M	$52.25M	$58.68M
Total Long-Term Liabilities	$362.5M	$420.9M	$367.3M
Total Liabilities	$648.5M	$473.1M	$429.7M
YoY Change	50.92%	-1.96%	0.85%
SHAREHOLDERS EQUITY
Retained Earnings	-$1.998B	-$1.913B	-$1.802B
YoY Change	10.87%	9.24%	14.56%
Common Stock	$228.0K	$228.0K	$196.0K
YoY Change	16.33%	16.33%	1.03%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$156.0M	-$104.3M	-$146.8M
YoY Change
Total Liabilities & Shareholders Equity	$492.5M	$332.3M	$282.9M
YoY Change	74.08%	2.81%	-43.14%

Cashflow Statement

Concept	2016 Q1	2015 Q4	2015 Q1
OPERATING ACTIVITIES
Net Income	-$59.22M	-$41.57M	-$33.25M
YoY Change	78.14%	-28.27%	-55.45%
Depreciation, Depletion And Amortization	$229.0K	$300.0K	$297.0K
YoY Change	-22.9%	-150.0%	-40.36%
Cash From Operating Activities	$156.8M	-$35.40M	-$45.09M
YoY Change	-447.8%	-29.2%	-37.46%
INVESTING ACTIVITIES
Capital Expenditures	$682.0K	-$300.0K	$31.00K
YoY Change	2100.0%		-91.93%
Acquisitions
YoY Change
Other Investing Activities	-$19.00M	$24.30M	$49.90M
YoY Change	-138.08%	-19.54%	-17.79%
Cash From Investing Activities	-$19.69M	$24.00M	$49.90M
YoY Change	-139.45%	-20.27%	-17.34%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$37.00K		$0.00
YoY Change			-100.0%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-$1.877M	7.400M	-$217.0K
YoY Change	764.98%	7300.0%	-100.33%
NET CHANGE
Cash From Operating Activities	$156.8M	-35.40M	-$45.09M
Cash From Investing Activities	-$19.69M	24.00M	$49.90M
Cash From Financing Activities	-$1.877M	7.400M	-$217.0K
Net Change In Cash	$135.2M	-4.000M	$4.592M
YoY Change	2845.3%	-79.8%	-91.43%
FREE CASH FLOW
Cash From Operating Activities	$156.8M	-$35.40M	-$45.09M
Capital Expenditures	$682.0K	-$300.0K	$31.00K
Free Cash Flow	$156.1M	-$35.10M	-$45.12M
YoY Change	-446.05%	-29.8%	-37.74%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2016Q1	dei	Amendment Flag AmendmentFlag	false
CY2016Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-30
CY2016Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2016Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2016
CY2016Q1	dei	Document Period End Date DocumentPeriodEndDate	2016-04-01
CY2016Q1	dei	Document Type DocumentType	10-Q
CY2016Q1	dei	Entity Central Index Key EntityCentralIndexKey	0000939767
CY2016Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	228739657	shares
CY2016Q1	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2016Q1	dei	Entity Registrant Name EntityRegistrantName	EXELIXIS, INC.
CY2016Q1	dei	Trading Symbol TradingSymbol	exel
CY2015Q4	exel	Accrued Collaboration Liability Current AccruedCollaborationLiabilityCurrent	10938000	USD
CY2016Q1	exel	Accrued Collaboration Liability Current AccruedCollaborationLiabilityCurrent	14674000	USD
CY2015Q4	exel	Cash Cash Equivalentsand Availableforsale Securities CashCashEquivalentsandAvailableforsaleSecurities	253310000	USD
CY2016Q1	exel	Cash Cash Equivalentsand Availableforsale Securities CashCashEquivalentsandAvailableforsaleSecurities	407617000	USD
CY2015Q4	exel	Cash Cash Equivalentsand Availableforsale Securities Amortized Cost Basis CashCashEquivalentsandAvailableforsaleSecuritiesAmortizedCostBasis	253433000	USD
CY2016Q1	exel	Cash Cash Equivalentsand Availableforsale Securities Amortized Cost Basis CashCashEquivalentsandAvailableforsaleSecuritiesAmortizedCostBasis	407551000	USD
CY2015Q4	exel	Cash Cash Equivalentsand Availableforsale Securities Gross Unrealized Gain Accumulatedin Investments CashCashEquivalentsandAvailableforsaleSecuritiesGrossUnrealizedGainAccumulatedinInvestments	7000	USD
CY2016Q1	exel	Cash Cash Equivalentsand Availableforsale Securities Gross Unrealized Gain Accumulatedin Investments CashCashEquivalentsandAvailableforsaleSecuritiesGrossUnrealizedGainAccumulatedinInvestments	84000	USD
CY2015Q4	exel	Cash Cash Equivalentsand Availableforsale Securities Gross Unrealized Loss Accumulatedin Investments CashCashEquivalentsandAvailableforsaleSecuritiesGrossUnrealizedLossAccumulatedinInvestments	130000	USD
CY2016Q1	exel	Cash Cash Equivalentsand Availableforsale Securities Gross Unrealized Loss Accumulatedin Investments CashCashEquivalentsandAvailableforsaleSecuritiesGrossUnrealizedLossAccumulatedinInvestments	18000	USD
CY2016Q1	exel	Debt Collateral Number Of Affiliate Banks DebtCollateralNumberOfAffiliateBanks	1	affiliate
CY2016Q1	exel	Debt Collateral Number Of Required Investment Accounts DebtCollateralNumberOfRequiredInvestmentAccounts	1	account
CY2015Q1	exel	Increase Decreasein Accrued Collaboration Liability IncreaseDecreaseinAccruedCollaborationLiability	2966000	USD
CY2016Q1	exel	Increase Decreasein Accrued Collaboration Liability IncreaseDecreaseinAccruedCollaborationLiability	3736000	USD
CY2015Q1	exel	Marketable Securities Numberof Securities Sold MarketableSecuritiesNumberofSecuritiesSold	0	security
CY2016Q1	exel	Marketable Securities Numberof Securities Sold MarketableSecuritiesNumberofSecuritiesSold	1	security
CY2016Q1	exel	Restructuring Reserve Proceedsfrom Saleof Property Plantand Equipment RestructuringReserveProceedsfromSaleofPropertyPlantandEquipment	34000	USD
CY2015Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	6401000	USD
CY2016Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	5657000	USD
CY2015Q4	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	3629000	USD
CY2016Q1	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	6042000	USD
CY2015Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	18071000	USD
CY2016Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	16135000	USD
CY2015Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-232000	USD
CY2016Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-42000	USD
CY2015Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	1832741000	USD
CY2016Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	1842248000	USD
CY2015Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1660000	USD
CY2016Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	11185000	USD
CY2015Q1	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	7675000	USD
CY2016Q1	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	5285000	USD
CY2015Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	118599000	shares
CY2016Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	120372000	shares
CY2015Q4	us-gaap	Assets Assets	332342000	USD
CY2016Q1	us-gaap	Assets Assets	492533000	USD
CY2015Q4	us-gaap	Assets Current AssetsCurrent	178665000	USD
CY2016Q1	us-gaap	Assets Current AssetsCurrent	339468000	USD
CY2015Q4	us-gaap	Assets Fair Value Disclosure Recurring AssetsFairValueDisclosureRecurring	250687000	USD
CY2016Q1	us-gaap	Assets Fair Value Disclosure Recurring AssetsFairValueDisclosureRecurring	405257000	USD
CY2015Q4	us-gaap	Available For Sale Securities AvailableForSaleSecurities	250687000	USD
CY2016Q1	us-gaap	Available For Sale Securities AvailableForSaleSecurities	405257000	USD
CY2015Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	7000	USD
CY2016Q1	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	84000	USD
CY2015Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	130000	USD
CY2016Q1	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	18000	USD
CY2015Q4	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	250810000	USD
CY2016Q1	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	405191000	USD
CY2016Q1	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss	18000	USD
CY2016Q1	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Less Than Twelve Months Fair Value AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue	37900000	USD
CY2016Q1	us-gaap	Available For Sale Securities Debt Maturities After One Through Five Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue	3252000	USD
CY2016Q1	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	402005000	USD
CY2016Q1	us-gaap	Available For Sale Securities In Unrealized Loss Positions Qualitative Disclosure Number Of Positions Less Than One Year AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsLessThanOneYear	19	investment
CY2014Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	80395000	USD
CY2015Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	84987000	USD
CY2015Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	141634000	USD
CY2016Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	276882000	USD
CY2015Q1	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	4592000	USD
CY2016Q1	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	135248000	USD
CY2016Q1	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	323300000	USD
CY2015Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2016Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2015Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2016Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2015Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	400000000	shares
CY2016Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	400000000	shares
CY2015Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	227960943	shares
CY2016Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	228681197	shares
CY2015Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	227960943	shares
CY2016Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	228681197	shares
CY2015Q4	us-gaap	Common Stock Value CommonStockValue	228000	USD
CY2016Q1	us-gaap	Common Stock Value CommonStockValue	228000	USD
CY2015Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-35110000	USD
CY2016Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-61157000	USD
CY2015Q1	us-gaap	Contracts Revenue ContractsRevenue	0	USD
CY2016Q1	us-gaap	Contracts Revenue ContractsRevenue	6328000	USD
CY2015Q4	us-gaap	Convertible Debt Current ConvertibleDebtCurrent	0	USD
CY2016Q1	us-gaap	Convertible Debt Current ConvertibleDebtCurrent	27500000	USD
CY2015Q4	us-gaap	Convertible Debt Noncurrent ConvertibleDebtNoncurrent	301435000	USD
CY2016Q1	us-gaap	Convertible Debt Noncurrent ConvertibleDebtNoncurrent	281156000	USD
CY2015Q1	us-gaap	Cost Of Goods Sold CostOfGoodsSold	766000	USD
CY2016Q1	us-gaap	Cost Of Goods Sold CostOfGoodsSold	685000	USD
CY2015Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	0	USD
CY2016Q1	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	14371000	USD
CY2015Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	0	USD
CY2016Q1	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	184431000	USD
CY2015Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	297000	USD
CY2016Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	229000	USD
CY2015Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.18
CY2016Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.27
CY2015Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	549000	USD
CY2016Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	0	USD
CY2015Q1	us-gaap	Fiscal Period Duration FiscalPeriodDuration	P371D
CY2016Q1	us-gaap	Fiscal Period Duration FiscalPeriodDuration	P364D
CY2015Q1	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	200000	USD
CY2016Q1	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-200000	USD
CY2013	us-gaap	Gain Loss On Sale Of Investments GainLossOnSaleOfInvestments	0	USD
CY2015Q1	us-gaap	Gain Loss On Sale Of Investments GainLossOnSaleOfInvestments	-1000	USD
CY2016Q1	us-gaap	Gain Loss On Sale Of Investments GainLossOnSaleOfInvestments	-1000	USD
CY2015Q1	us-gaap	Gain Loss On Sale Of Other Assets GainLossOnSaleOfOtherAssets	95000	USD
CY2016Q1	us-gaap	Gain Loss On Sale Of Other Assets GainLossOnSaleOfOtherAssets	0	USD
CY2015Q4	us-gaap	Goodwill Goodwill	63684000	USD
CY2016Q1	us-gaap	Goodwill Goodwill	63684000	USD
CY2015Q1	us-gaap	Increase Decrease In Accounts And Other Receivables IncreaseDecreaseInAccountsAndOtherReceivables	-1292000	USD
CY2016Q1	us-gaap	Increase Decrease In Accounts And Other Receivables IncreaseDecreaseInAccountsAndOtherReceivables	4938000	USD
CY2015Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-6382000	USD
CY2016Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	5333000	USD
CY2015Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-10569000	USD
CY2016Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-1936000	USD
CY2015Q1	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-2576000	USD
CY2016Q1	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	198802000	USD
CY2015Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	212000	USD
CY2016Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-144000	USD
CY2015Q1	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	115000	USD
CY2016Q1	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-241000	USD
CY2015Q1	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-288000	USD
CY2016Q1	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-258000	USD
CY2015Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1731000	USD
CY2016Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	985000	USD
CY2015Q1	us-gaap	Increase Decrease In Restricted Cash And Investments IncreaseDecreaseInRestrictedCashAndInvestments	-10748000	USD
CY2016Q1	us-gaap	Increase Decrease In Restricted Cash And Investments IncreaseDecreaseInRestrictedCashAndInvestments	-2004000	USD
CY2015Q1	us-gaap	Increase Decrease In Restructuring Reserve IncreaseDecreaseInRestructuringReserve	-3024000	USD
CY2016Q1	us-gaap	Increase Decrease In Restructuring Reserve IncreaseDecreaseInRestructuringReserve	-1057000	USD
CY2015Q1	us-gaap	Interest Expense InterestExpense	12403000	USD
CY2016Q1	us-gaap	Interest Expense InterestExpense	12414000	USD
CY2015Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	583000	USD
CY2016Q1	us-gaap	Inventory Finished Goods InventoryFinishedGoods	734000	USD
CY2015Q4	us-gaap	Inventory Gross InventoryGross	3871000	USD
CY2016Q1	us-gaap	Inventory Gross InventoryGross	3486000	USD
CY2015Q4	us-gaap	Inventory Net InventoryNet	2616000	USD
CY2016Q1	us-gaap	Inventory Net InventoryNet	2472000	USD
CY2015Q4	us-gaap	Inventory Noncurrent InventoryNoncurrent	1255000	USD
CY2016Q1	us-gaap	Inventory Noncurrent InventoryNoncurrent	1014000	USD
CY2015Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	1037000	USD
CY2016Q1	us-gaap	Inventory Raw Materials InventoryRawMaterials	1032000	USD
CY2015Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	2251000	USD
CY2016Q1	us-gaap	Inventory Work In Process InventoryWorkInProcess	1720000	USD
CY2016Q1	us-gaap	Inventory Write Down InventoryWriteDown	0	USD
CY2015Q4	us-gaap	Liabilities Liabilities	436646000	USD
CY2016Q1	us-gaap	Liabilities Liabilities	648487000	USD
CY2015Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	332342000	USD
CY2016Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	492533000	USD
CY2015Q4	us-gaap	Liabilities Current LiabilitiesCurrent	52251000	USD
CY2016Q1	us-gaap	Liabilities Current LiabilitiesCurrent	101067000	USD
CY2015Q4	us-gaap	Long Term Debt LongTermDebt	381435000	USD
CY2016Q1	us-gaap	Long Term Debt LongTermDebt	388656000	USD
CY2015Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	0	USD
CY2016Q1	us-gaap	Long Term Debt Current LongTermDebtCurrent	27500000	USD
CY2015Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	381435000	USD
CY2016Q1	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	361156000	USD
CY2015Q4	us-gaap	Long Term Investments LongTermInvestments	83600000	USD
CY2016Q1	us-gaap	Long Term Investments LongTermInvestments	82850000	USD
CY2015Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	80000000	USD
CY2016Q1	us-gaap	Long Term Notes Payable LongTermNotesPayable	80000000	USD
CY2015Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-217000	USD
CY2016Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	37000	USD
CY2015Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	49895000	USD
CY2016Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-19685000	USD
CY2015Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-45086000	USD
CY2016Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	154896000	USD
CY2015Q1	us-gaap	Net Income Loss NetIncomeLoss	-35170000	USD
CY2016Q1	us-gaap	Net Income Loss NetIncomeLoss	-61347000	USD
CY2015Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-12410000	USD
CY2016Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-12212000	USD
CY2016Q1	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2015Q1	us-gaap	Operating Expenses OperatingExpenses	32148000	USD
CY2016Q1	us-gaap	Operating Expenses OperatingExpenses	64562000	USD
CY2015Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-22760000	USD
CY2016Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-49135000	USD
CY2015Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	10007000	USD
CY2016Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	13671000	USD
CY2015Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	2309000	USD
CY2016Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	2068000	USD
CY2015Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	60000	USD
CY2016Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	190000	USD
CY2015Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	1575000	USD
CY2016Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	1317000	USD
CY2016Q1	us-gaap	Other Long Term Investments OtherLongTermInvestments	81600000	USD
CY2015Q1	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-637000	USD
CY2016Q1	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	1474000	USD
CY2015Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-7000	USD
CY2016Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	202000	USD
CY2015Q1	us-gaap	Paid In Kind Interest PaidInKindInterest	0	USD
CY2016Q1	us-gaap	Paid In Kind Interest PaidInKindInterest	1936000	USD
CY2016Q1	us-gaap	Payments For Restructuring PaymentsForRestructuring	1151000	USD
CY2015Q1	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	13282000	USD
CY2016Q1	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	49235000	USD
CY2015Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	31000	USD
CY2016Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	682000	USD
CY2015Q1	us-gaap	Payments To Acquire Restricted Investments PaymentsToAcquireRestrictedInvestments	2684000	USD
CY2016Q1	us-gaap	Payments To Acquire Restricted Investments PaymentsToAcquireRestrictedInvestments	2004000	USD
CY2015Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2016Q1	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2015Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3806000	USD
CY2016Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	4791000	USD
CY2015Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	USD
CY2016Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	37000	USD
CY2015Q1	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	54410000	USD
CY2016Q1	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	30108000	USD
CY2015Q1	us-gaap	Proceeds From Repayments Of Notes Payable ProceedsFromRepaymentsOfNotesPayable	-217000	USD
CY2016Q1	us-gaap	Proceeds From Repayments Of Notes Payable ProceedsFromRepaymentsOfNotesPayable	0	USD
CY2015Q1	us-gaap	Proceeds From Sale And Maturity Of Other Investments ProceedsFromSaleAndMaturityOfOtherInvestments	95000	USD
CY2016Q1	us-gaap	Proceeds From Sale And Maturity Of Other Investments ProceedsFromSaleAndMaturityOfOtherInvestments	0	USD
CY2015Q1	us-gaap	Proceeds From Sale Of Available For Sale Securities ProceedsFromSaleOfAvailableForSaleSecurities	0	USD
CY2016Q1	us-gaap	Proceeds From Sale Of Available For Sale Securities ProceedsFromSaleOfAvailableForSaleSecurities	17000	USD
CY2015Q1	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	639000	USD
CY2016Q1	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	107000	USD
CY2015Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1434000	USD
CY2016Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1813000	USD
CY2015Q4	us-gaap	Receivables Net Current ReceivablesNetCurrent	5183000	USD
CY2016Q1	us-gaap	Receivables Net Current ReceivablesNetCurrent	10088000	USD
CY2015Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	22282000	USD
CY2016Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	28926000	USD
CY2015Q4	us-gaap	Restricted Cash And Investments Noncurrent RestrictedCashAndInvestmentsNoncurrent	2650000	USD
CY2016Q1	us-gaap	Restricted Cash And Investments Noncurrent RestrictedCashAndInvestmentsNoncurrent	2650000	USD
CY2016Q1	us-gaap	Restructuring And Related Cost Expected Cost1 RestructuringAndRelatedCostExpectedCost1	200000	USD
CY2015Q1	us-gaap	Restructuring Charges RestructuringCharges	-431000	USD
CY2016Q1	us-gaap	Restructuring Charges RestructuringCharges	94000	USD
CY2015Q4	us-gaap	Restructuring Reserve RestructuringReserve	4590000	USD
CY2016Q1	us-gaap	Restructuring Reserve RestructuringReserve	3533000	USD
CY2016Q1	us-gaap	Restructuring Reserve Accrual Adjustment RestructuringReserveAccrualAdjustment	34000	USD
CY2015Q4	us-gaap	Restructuring Reserve Current RestructuringReserveCurrent	3205000	USD
CY2016Q1	us-gaap	Restructuring Reserve Current RestructuringReserveCurrent	3017000	USD
CY2015Q4	us-gaap	Restructuring Reserve Noncurrent RestructuringReserveNoncurrent	1385000	USD
CY2016Q1	us-gaap	Restructuring Reserve Noncurrent RestructuringReserveNoncurrent	516000	USD
CY2015Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1937041000	USD
CY2016Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1998388000	USD
CY2015Q1	us-gaap	Revenue Recognition Sales Returns Reserve For Sales Returns RevenueRecognitionSalesReturnsReserveForSalesReturns	0	USD
CY2016Q1	us-gaap	Revenue Recognition Sales Returns Reserve For Sales Returns RevenueRecognitionSalesReturnsReserveForSalesReturns	500000	USD
CY2015Q1	us-gaap	Revenues Revenues	9388000	USD
CY2016Q1	us-gaap	Revenues Revenues	15427000	USD
	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	83400000	USD
CY2015Q1	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	9388000	USD
CY2016Q1	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	9099000	USD
CY2015Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	9531000	USD
CY2016Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	34857000	USD
CY2015Q1	us-gaap	Share Based Compensation ShareBasedCompensation	1660000	USD
CY2016Q1	us-gaap	Share Based Compensation ShareBasedCompensation	11185000	USD
CY2016Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	18979572	shares
CY2016Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	4.23
CY2016Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	116788	shares
CY2016Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	2062850	shares
CY2016Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	28038000	USD
CY2015Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	27425854	shares
CY2016Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	29350416	shares
CY2015Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	4.22
CY2016Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	4.22
CY2016Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	1.70
CY2016Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	3.26
CY2016Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	4.17
CY2016Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	20380000	USD
CY2016Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P4Y4M2D
CY2016Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P4Y11M19D
CY2015Q4	us-gaap	Short Term Investments ShortTermInvestments	25426000	USD
CY2016Q1	us-gaap	Short Term Investments ShortTermInvestments	45235000	USD
CY2016Q1	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	21500	shares
CY2015Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-104304000	USD
CY2016Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-155954000	USD
CY2015Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	195904000	shares
CY2016Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	228304000	shares
CY2016Q1	us-gaap	Fiscal Period FiscalPeriod	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We adopted a 52- or 53-week fiscal year that generally ends on the Friday closest to December 31st. Fiscal year 2016 will end on December 30, 2016, and fiscal year 2015, ended on January 1, 2016. For convenience, references in this report as of and for the fiscal periods ended April 1, 2016 and March 28, 2015, and as of and for the fiscal years ended December 30, 2016 and January 1, 2016, are indicated as being as of and for the periods ended March 31, 2016, March 31, 2015, December 31, 2016, and December 31, 2015, respectively.</font><font style="font-family:inherit;font-size:10pt;"> </font></div></div>
CY2016Q1	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:18px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of our consolidated financial statements is in conformity with accounting principles generally accepted in the United States which requires management to make judgments, estimates and assumptions that affect the reported amounts of assets, liabilities, revenue and expenses, and related disclosures. On an ongoing basis, management evaluates its estimates including, but not limited to, those related to revenue recognition, including for deductions from revenues (such as rebates, chargebacks, sales returns and sales allowances) </font><font style="font-family:Times New Roman;font-size:10pt;">and the period of performance, identification of deliverables and evaluation of milestones with respect to our collaborations</font><font style="font-family:inherit;font-size:10pt;">, recoverability of inventory, certain accrued liabilities including clinical trial and collaboration liability accruals, and share-based compensation. We base our estimates on historical experience and on various other market-specific and other relevant assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ materially from those estimates.</font><font style="font-family:inherit;font-size:10pt;"> </font></div></div>

Files In Submission

Name	View Source	Status
0000939767-16-000188-index-headers.html	Edgar Link	pending
0000939767-16-000188-index.html	Edgar Link	pending
0000939767-16-000188.txt	Edgar Link	pending
0000939767-16-000188-xbrl.zip	Edgar Link	pending
cabomalatesalt.gif	Edgar Link	pending
exel-20160401.xml	Edgar Link	completed
exel-20160401.xsd	Edgar Link	pending
exel-20160401_cal.xml	Edgar Link	unprocessable
exel-20160401_def.xml	Edgar Link	unprocessable
exel-20160401_lab.xml	Edgar Link	unprocessable
exel-20160401_pre.xml	Edgar Link	unprocessable
exel.gif	Edgar Link	pending
exel2016033110-q.htm	Edgar Link	pending
exel20160331exhibit103.htm	Edgar Link	pending
exel20160331exhibit104.htm	Edgar Link	pending
exel20160331exhibit121.htm	Edgar Link	pending
exel20160331exhibit311.htm	Edgar Link	pending
exel20160331exhibit312.htm	Edgar Link	pending
exel20160331exhibit321.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
ipsenlogo.gif	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$EXEL
EXELIXIS, INC. Stock $exel

2016 Q1 Form 10-Q Financial Statement

#000093976716000188 Filed on May 04, 2016

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$EXEL EXELIXIS, INC. Stock $exel

2016 Q1 Form 10-Q Financial Statement

#000093976716000188 Filed on May 04, 2016

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$EXEL
EXELIXIS, INC. Stock $exel